Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Jul;28(1):138–140. doi: 10.1128/aac.28.1.138

Cefotaxime diffusion into cerebrospinal fluid of children with meningitis.

B I Asmar, M C Thirumoorthi, J A Buckley, D M Kobos, A S Dajani
PMCID: PMC176325  PMID: 4037772

Abstract

Cefotaxime diffused consistently and in therapeutic levels into the cerebrospinal fluid (CSF) of 13 children successfully treated for bacterial meningitis. CSF cefotaxime levels early (6.0 micrograms/ml) and late (1.2 micrograms/ml) in treatment were severalfold the MBCs for the infecting organisms. After a single 40-mg/kg dose to each of five infants with ventriculostomies, mean CSF levels of cefotaxime were 6.4, 5.7, and 4.5 micrograms/ml at 2, 4, and 6 h, respectively.

Full text

PDF
138

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belohradsky B. H., Bruch K., Geiss D., Kafetzis D., Marget W., Peters G. Intravenous cefotaxime in children with bacterial meningitis. Lancet. 1980 Jan 12;1(8159):61–63. doi: 10.1016/s0140-6736(80)90491-2. [DOI] [PubMed] [Google Scholar]
  2. Chamberlain J., Coombes J. D., Dell D., Fromson J. M., Ings R. J., Macdonald C. M., McEwen J. Metabolism of cefotaxime in animals and man. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):69–78. doi: 10.1093/jac/6.suppl_a.69. [DOI] [PubMed] [Google Scholar]
  3. Decazes J. M., Ernst J. D., Sande M. A. Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis. Antimicrob Agents Chemother. 1983 Oct;24(4):463–467. doi: 10.1128/aac.24.4.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Feldman W. E., Ginsburg C. M., McCracken G. H., Jr, Allen D., Ahmann P., Graham J., Graham L. Relation of concentrations of Haemophilus influenzae type b in cerebrospinal fluid to late sequelae of patients with meningitis. J Pediatr. 1982 Feb;100(2):209–212. doi: 10.1016/s0022-3476(82)80636-7. [DOI] [PubMed] [Google Scholar]
  5. Hamilton-Miller J. M., Brumfitt W., Reynolds A. V. Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro. J Antimicrob Chemother. 1978 Sep;4(5):437–444. doi: 10.1093/jac/4.5.437. [DOI] [PubMed] [Google Scholar]
  6. Humbert G., Leroy A., Nair S. R., Cherubin C. E. Concentrations of cefotaxime and the desacetyl metabolite in serum and CSF of patients with meningitis. J Antimicrob Chemother. 1984 May;13(5):487–494. doi: 10.1093/jac/13.5.487. [DOI] [PubMed] [Google Scholar]
  7. Kafetzis D. A., Brater D. C., Kapiki A. N., Papas C. V., Dellagrammaticas H., Papadatos C. J. Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics. J Pediatr. 1982 Mar;100(3):483–489. doi: 10.1016/s0022-3476(82)80466-6. [DOI] [PubMed] [Google Scholar]
  8. Kauffman R. E., Miceli J. N., Strebel L., Buckley J. A., Done A. K., Dajani A. S. Pharmacokinetics of chloramphenicol and chloramphenicol succinate in infants and children. J Pediatr. 1981 Feb;98(2):315–320. doi: 10.1016/s0022-3476(81)80670-1. [DOI] [PubMed] [Google Scholar]
  9. Kauffman R. E., Thirumoorthi M. C., Buckley J. A., Aravind M. K., Dajani A. S. Relative bioavailability of intravenous chloramphenicol succinate and oral chloramphenicol palmitate in infants and children. J Pediatr. 1981 Dec;99(6):963–967. doi: 10.1016/s0022-3476(81)80034-0. [DOI] [PubMed] [Google Scholar]
  10. Lecaillon J. B., Rouan M. C., Souppart C., Febvre N., Juge F. Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1982 Mar 12;228:257–267. doi: 10.1016/s0378-4347(00)80438-7. [DOI] [PubMed] [Google Scholar]
  11. Neu H. C., Aswapokee P., Fu K. P., Ho I., Matthijssen C. Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses. Clin Pharmacol Ther. 1980 May;27(5):677–685. doi: 10.1038/clpt.1980.96. [DOI] [PubMed] [Google Scholar]
  12. Neu H. C. The pharmacokinetics of new cephalosporins: significance in clinical practice. Bull N Y Acad Med. 1984 May;60(4):327–339. [PMC free article] [PubMed] [Google Scholar]
  13. Weeks J. L., Mason E. O., Jr, Baker C. J. Antagonism of ampicillin and chloramphenicol for meningeal isolates of group B streptococci. Antimicrob Agents Chemother. 1981 Sep;20(3):281–285. doi: 10.1128/aac.20.3.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wise R., Rollason T., Logan M., Andrews J. M., Bedford K. A. HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother. 1978 Dec;14(6):807–811. doi: 10.1128/aac.14.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES